Patient FAQ

Is PAMP-immunotherapy restricted to particular forms of cancer ?

PAMP-immunotherapy ist a general immune stimulatory method aimed at strengthening and amplifying an extant immune reaction against cancer cells, which is present in many if not most cancer patients. 

Even if there are several indications from experiments in cancer mice, that PAMP-therapy might have positive effects, often results in mice cannot be propagated into man. Are there results in humans ?  

First, we have to mention the old, often extraordinary results achieved by Coley and contemporaries in the years  1895-1936 in cancer patients (see "Healing Heat", amazon 2016). They used PAMP (see definitions and general FAQ) containing bacterial extracts, we use approved PAMP containing drugs. We are quite certain that PAMP substances from pathogens are the common denominator. Apart from different "PAMP vectors" we try to orient towards Coley's therapy recommendations.

Further there are anecdotal reports from cancer treatments using Vaccineurin in the 1960ies to 1980ies in Germany. Vaccineurin was a drug similar to Coley's preparation but not approved for cancer therapy. These results have never been formally published - they were done in private clinics on a sub-academic level - but healings even from aggressive cancers such as pancreatic cancer have been reported by witnesses. 

In newer times we have several positive reports using mistletoe extract - mistletoe lectin is a PAMP - in high dosage, multimodal settings, as well as other fever induction therapies (see case studies in  "Healing Heat"). These cases were not done according to the - more recent - AMT protocol, but presumably immune stimulatory effects were triggered by PAMP in all these cases. We hope that PAMP-immunotherapy due to synergistic effects from multiple PAMP combined can be even more powerful.  

A cheap cancer treatment without severe adverse effects sound too good to be true- Why is PAMP-immunotherapy not yet broadly established ? 

PAMP-immunotherapy is new. We have formally published the method in 2016.  A treatment protocol for physicians is in place. Several patients are treated according to our protocol. 

There are some obstacles.

In the 1960ies several groups have tried to repeat Coley's success story. Some remissions were reported, even cures, but the high success rate of Coley - for instance, more than 80% of inoperable, late stage sarcomas were cured - could not be reclaimed. The overall understanding in the oncological community was "it does not work". Yet, it must be confessed that several crucial determinants of Coley's protocoll were not adhered to, which we now try to regain with PAMP-immunotherapy. 

Secondly, there is a common understanding that the human body can not defeat cancer. This is plain wrong, as hundreds of reports on spontaneous healings indicate. 

Third, there is some ingrained reservation among physicians with respect to fever and thus to tackle PAMP-immunotherapy. This needs to change. 

On top, at least in Germany many Leitlinien (guidelines) stand in the way. Leitlinien, for most forms of cancer, recommend chemotherapy and/or radiotherapy as soon as possible after diagnosis. We need, however, a window of three to five weeks before immune compromising therapies start. PAMP-immunotherapy requires, ideally, an uncompromised immune system.  With respect to the very slow pace of development of most forms of cancer, the urgency indicated in the Leitlinien appears debatable, yet most clinical physicians have learned to adhere closely to Leitlinien.

And than there is the open question of financing. There are no Kassenziffern (refunding items) for PAMP-immunotherapy yet, so doctors have to find auxilliary refunding items or may restrict to private health insurances. 

The average patient usually is channelled by his house practitioner into one of the big cancer clinics, where PAMP-immunotherapy is unknown yet. Clinics where PAMP-immunotherapy is known are listed in the patients information leaflet

From immunology and first modern case studies on fever therapy we are confident that PAMP-immunotherapy can benefit patients. At any rate, PAMP-immunotherapy is one of the first alternative therapies to consider. 

How expensive is PAMP-immunotherapy ? 

Pure drug costs for five weeks PAMP-immunotherapy are about 400 Euro (pharmacy OTC)  in Germany. In semi-stationary or stationary settings, costs for bed, nutrition and circulation monitoring add up. 

Can a general practitioner treat according to PAMP-immunotherapy ? 

In principle, yes. There should be a restroom and instruments for monitoring circulation. 

How does the treatment look like ? 

Patients appear with a sober stomach in the morning to get an infusion of three PAMP drugs combined over 2-3 hours. The first week is dedicated to finding the correct dosage, which may be different from patient to patient. We start with a very low dose and increase day by day, until fever develops. This will be the dose for the next two to four weeks of treatment, with two to three infusions per week (see patients information leaflet).

Usually fever peaks 1-2 hours after infusion and declines till evening. Often patients have a healthy appetite after treatment. Sometimes a few days after treatment patients report increased physical and mental power. 

Are severe adverse effect to expect ? 

In one case reported to us dose was not increased stepwise but treatment started with a high dose of a PAMP substance (not among our drug recommendations). In this case a non-fatal circulatory collapse occured.

Coley from more than 30 years of treatment experience reported six cases of tumour lysis syndrome, where the damage to the malignancy imposed by the immune system was so strong that kidneys could not cope. In case of tumour lysis syndrome further treatment has to be delayed a few days. Otherwise we can expect those unpleasant symptoms we see during a proliferative infection. 

Are three fever inductions per week over four weeks required ? 

Coley had the feeling that his successes correlated with number and short frequency of fever induction. Weak patients may benefit from  sub-febrile high-frequency vaccinations as well.

Would you do PAMP-immunotherapy to yourself ?

Sure enough.

 (C) Uwe Hobohm